3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Glioblastoma
12
Brain Neoplasms
6
Gliosarcoma
5
Astrocytoma
4
Recurrence
3
Oligodendroglioma
3
Lymphoma, Follicular
3
Carcinoma, Non-Small-Cell Lung
3
Prostatic Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Optic Nerve Glioma
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Glioma
2
Diffuse Intrinsic Pontine Glioma
2
Central Nervous System Neoplasms
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Interventions
Vinorelbine
1
Temozolomide
1
Radiotherapy
1
Genz-644282
1
Gemcitabine
1
Everolimus
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metatropic dwarfism
×
Cilengitide
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts